Cargando…

Homocysteine Levels in Parkinson's Disease: Is Entacapone Effective?

Plasma homocysteine (Hcy) levels may increase in levodopa-treated patients with Parkinson's disease (PD) as a consequence of levodopa methylation via catechol-O-methyltransferase (COMT). Results from previous studies that assessed the effect of COMT inhibitors on levodopa-induced hyperhomocyste...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kocer, Bilge, Guven, Hayat, Comoglu, Selim Selcuk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4967439/ https://www.ncbi.nlm.nih.gov/pubmed/27493964 http://dx.doi.org/10.1155/2016/7563705

Ejemplares similares

The Effect of Hyperhomocysteinemia on Motor Symptoms, Cognitive Status, and Vascular Risk in Patients with Parkinson's Disease
por: Kocer, Bilge, et al.
Publicado: (2016)

Bone mass and vitamin D levels in Parkinson’s disease: is there any difference between genders?
por: Ozturk, Erhan Arif, et al.
Publicado: (2016)

Early Recurrence of Holmes Tremor after Radiofrequency Thalamotomy
por: Onder, Halil, et al.
Publicado: (2022)

Dramatic Recovery of Freezing of Gait with Subthalamic Nucleus Deep Brain Stimulation
por: Onder, Halil, et al.
Publicado: (2022)

The Temporal Course of the MRI Findings of Inferior Oliver Hypertrophy: The Clinicoradiologic Presentation of a Rare Patient with Holmes Tremor and Palatal Myoclonus
por: Onder, Halil, et al.
Publicado: (2022)

Experience Reduces Surgical and Hardware-Related Complications of Deep Brain Stimulation Surgery: A Single-Center Study of 181 Patients Operated in Six Years
por: Sorar, Mehmet, et al.
Publicado: (2018)

The Detailed İnvestigation of Eyelid-Opening Apraxia after Subthalamic Nucleus Deep Brain Stimulation
por: Comoglu, Selcuk, et al.
Publicado: (2022)

Therapeutic Effect of Levodopa/Carbidopa/Entacapone on Sleep Disturbance in Patients with Parkinson’s Disease
por: Park, Kye Won, et al.
Publicado: (2020)

Bilateral Posteroventral GPi-DBS in a Patient with Tourette’s Syndrome – A Rapidly Effective But Under-utilized Therapy
por: Onder, Halil, et al.
Publicado: (2023)

Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson’s disease
por: Poulopoulos, Markos, et al.
Publicado: (2010)

The Overlap in Neuroimaging Findings Between Idiopathic Normal Pressure Hydrocephalus and Progressive Supranuclear Palsy
por: Önder, Halil, et al.
Publicado: (2022)

One-Year Open-Label Study of Entacapone in Patients with Advanced Parkinson Disease
por: Ahn, Tae-Beom, et al.
Publicado: (2007)

Opicapone Efficacy and Tolerability in Parkinson's Disease Patients Reporting Insufficient Benefit/Failure of Entacapone
por: Vokurka, Petr, et al.
Publicado: (2020)

Impaired trunk control and its relationship with balance, functional mobility, and disease severity in patients with cervical dystonia
por: SÖKE, Fatih, et al.
Publicado: (2022)

Levodopa/carbidopa and entacapone in the treatment of Parkinson’s disease: efficacy, safety and patient preference
por: Müller, Thomas
Publicado: (2009)

Population pharmacokinetics of levodopa gel infusion in Parkinson’s disease: effects of entacapone infusion and genetic polymorphism
por: Senek, M., et al.
Publicado: (2020)

Entacapone Reduces Cortical Activation in Parkinson's Disease with Wearing-Off: A f-MRI Study
por: Tambasco, Nicola, et al.
Publicado: (2014)

Lymphocytic colitis associated with entacapone
por: Rodrigues, David M., et al.
Publicado: (2022)

Entacapone promotes hippocampal neurogenesis in mice
por: Yoo, Dae Young, et al.
Publicado: (2020)

Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson’s Disease Patients
por: Müller, Thomas, et al.
Publicado: (2022)

Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo(®))
por: Solla, Paolo, et al.
Publicado: (2010)

Correction to “Lymphocytic colitis associated with entacapone”
Publicado: (2022)

A Pilot Study Exploring the Association of Entacapone, Gut Microbiota, and the Subsequent Side Effects in Patients With Parkinson’s Disease
por: Fu, Shih-Chen, et al.
Publicado: (2022)

Letter Regarding the Article Entitled: “The Effect of Dual Tasking and Deep Brain Stimulation Frequency Parameters on Gait in Advanced Parkinson's Disease”
por: Onder, Halil, et al.
Publicado: (2022)

Pumpentherapie bei fortgeschrittenem Parkinson-Syndrom: Charakterisierung des Intestinalgels Levodopa-Entacapon-Carbidopa
por: H. Jost, Wolfgang, et al.
Publicado: (2022)

Colite lymphocytaire associée à l’entacapone
por: Rodrigues, David M., et al.
Publicado: (2023)

Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off
por: Kuoppamäki, Mikko, et al.
Publicado: (2015)

A Rare Patient with Hereditary Spastic Paraparesis with Parkinsonism
por: Onder, Halil, et al.
Publicado: (2023)

Controlled-Release Levodopa for the Treatment of Rapid Motor Fluctuations in Parkinson's Disease Subjects with Subthalamic Nucleus Deep Brain Stimulation
por: Onder, Halil, et al.
Publicado: (2023)

Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
por: Brooks, David J
Publicado: (2008)

Levodopa–entacapone–carbidopa intestinal gel infusion in advanced Parkinson’s disease: real-world experience and practical guidance
por: Nyholm, Dag, et al.
Publicado: (2022)

Subjective Assessments of Voice in Parkinson’s Disease Subjects with and without STN-DBS Therapy
por: Onder, Halil, et al.
Publicado: (2023)

Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo(®) 200) in the treatment of Parkinson’s disease: a case series
por: Sethi, Kapil D, et al.
Publicado: (2009)

The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone
por: Leta, Valentina, et al.
Publicado: (2023)

Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson’s disease: systematic review, meta-analysis, and economic evaluation
por: Yi, Zhan-Miao, et al.
Publicado: (2018)

Homocysteine levels, genetic background, and cognitive impairment in Parkinson’s disease
por: Periñán, María Teresa, et al.
Publicado: (2022)

Entacapone Treatment Modulates Hippocampal Proteins Related to Synaptic Vehicle Trafficking
por: Yoo, Dae Young, et al.
Publicado: (2020)

Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice
por: Öthman, Mezin, et al.
Publicado: (2021)

The effects of hemodialysis and peritoneal dialysis on serum homocysteine and C-reactive protein levels.
por: Borazan, Ali, et al.
Publicado: (2004)

Serum Homocysteine Level in Parkinson's Disease and Its Association with Duration, Cardinal Manifestation, and Severity of Disease
por: Saadat, Payam, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_oi386r3c9crqa9bsms3muk6gpa